Role of imaging in multiple myeloma.
Francis I BaffourKatrina N GlazebrookShaji K KumarStephen M BroskiPublished in: American journal of hematology (2020)
With rapid advancements in the diagnosis and treatment of multiple myeloma (MM), imaging has become instrumental in detection of intramedullary and extramedullary disease, providing prognostic information, and assessing therapeutic efficacy. Whole-body low dose computed tomography (WBLDCT) has emerged as the study of choice to detect osteolytic bone disease. Positron emission tomography/computed tomography (PET/CT) combines functional and morphologic information to identify MM disease activity and assess treatment response. Magnetic resonance imaging (MRI) has excellent soft-tissue contrast and is the modality of choice for bone marrow evaluation. This review focuses on the imaging modalities available for MM patient management, highlighting advantages, disadvantages, and applications of each.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- magnetic resonance imaging
- contrast enhanced
- multiple myeloma
- disease activity
- high resolution
- low dose
- bone marrow
- soft tissue
- systemic lupus erythematosus
- rheumatoid arthritis
- pet imaging
- loop mediated isothermal amplification
- dual energy
- high dose
- magnetic resonance
- healthcare
- ankylosing spondylitis
- mesenchymal stem cells
- health information
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- quantum dots
- fluorescence imaging
- photodynamic therapy
- sensitive detection